Table 6.
Risk of Brain Metastasis Associated with Each Marker in Breast Cancer
| Brain metastasis marker | UniProtKB ID | Sensitivity⁎ | Specificity⁎ | LR |
P value† | |
|---|---|---|---|---|---|---|
| Pos | Neg | |||||
| ErbB-2 | P04626 | 8/13 (61.5) | 90/99 (90.9) | 6.70 | 0.42 | <0.0001 |
| GRP94 | P14625 | 12/13 (92.0) | 55/107 (51.4) | 1.89 | 0.16 | 0.003 |
| FN14 | Q9NP84 | 9/13 (69.2) | 80/104 (77.0) | 3.01 | 0.40 | 0.001 |
| TRAF2 | Q12933 | 9/11 (81.8) | 45/88 (51.1) | 1.67 | 0.35 | 0.055 |
| VAV2 | P52735 | 2/13 (15,4) | 95/107 (88.8) | 1.38 | 0.95 | 0.65 |
| TOP1 | Q9UJN0‡ | 4/13 (30.8) | 91/105 (86.6) | 2.30 | 0.80 | 0.11 |
| Inhibin | P05111) | 0/13 (0) | 97/107 (90.7) | 0 | 1.10 | 0.60 |
LR, likelihood ratio; Neg, negative LR; Pos, positive LR.
⁎
Variation in denominators derives from missing values in the IHC (eg, tissue lost, unviable staining, or background).
†
Fisher's exact test, 2-sided.
‡
Secondary accession number. The primary (citable) accession number is number is P11387.